The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kotov S.V.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Kudlay D.A.

Institute for Advanced Studies of the Federal Medical and Biological Agency, Moscow, Russia

Lizhdvoĭ V.Iu.

Stashuk G.A.

GBUZ MO "Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo", Moskva

Magomedova S.B.

Vladimirskiy Moscow Regional Research Clinical Institute, Moscow, Russia

A study of the efficacy of infibeta in patients with multiple sclerosis based on NEDA-3

Authors:

Kotov S.V., Kudlay D.A., Lizhdvoĭ V.Iu., Stashuk G.A., Magomedova S.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2): 107‑115

DOI: 10.17116/jnevro201911922107

Views: 1681

Downloaded: 55

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Kotov SV, Kudlay DA, Lizhdvoĭ VIu, Stashuk GA, Magomedova SB. A study of the efficacy of infibeta in patients with multiple sclerosis based on NEDA-3. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2):107‑115. (In Russ.)
https://doi.org/10.17116/jnevro201911922107

 
МСФ на ЯМ
Close metadata

Objective. The two-year study of the efficacy of Ifnb-1B (infibeta) in patients with relapsing-remitting (RRS) and secondary progressive multiple sclerosis (SPMS) in the Moscow region with the criteria NEDA-3. Material and methods. Three hundred patients, 81 men and 219 women, aged from 18 to 67 years, including 227 with RRS and 73 with SPMS, were studied. The duration of disease was from 0.5 to 39 years, the level of neurological deficit on EDSS scale was from 1 to 6.5 points. All patients received infibeta. Results and conclusion. During the treatment with infibeta, the chance of exacerbation decreased by an average of 39.4 times (OR 39.4 95% CI; 16.6—122.7) during the first year, by 35.3 times (OR 35.3; 95% CI 13.5—131,2) during the second year. A statistically significant decrease in the probability of exacerbation is also confirmed in the conditional logistic regression model (p<0.001). MRI revealed the signs of exacerbation and progression of the disease only in 11.5% of patients; 54.9% of the patients met the criteria NEDA-3. The highest efficacy of infibeta is noted in patients with RRS, more than 3/4 of them responded to therapy with the absence of both clinical and MRI signs of exacerbation and increase in neurodegeneration. Thus, a good clinical result is achieved in patients with RRS and SPMS treated with infibeta. When using the NEDA-3 criteria, a positive result is achieved in more than half of patients.

Keywords:

multiple sclerosis
interferon b-1b
efficacy
no evidence of disease activity
NEDA-3

Authors:

Kotov S.V.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Kudlay D.A.

Institute for Advanced Studies of the Federal Medical and Biological Agency, Moscow, Russia

Lizhdvoĭ V.Iu.

Stashuk G.A.

GBUZ MO "Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo", Moskva

Magomedova S.B.

Vladimirskiy Moscow Regional Research Clinical Institute, Moscow, Russia

List of references:

  1. Fisniku LK, Brex P, Altmann D, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808-817.
  2. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56(12):1628-1636.
  3. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29(9):2031-2048.
  4. Cohen BA, Rivera VM. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010;26(4):827-838. https://doi.org/10.1185/03007991003604018
  5. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R, BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-397.
  6. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65(12):1919-1923.
  7. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F; LORSEP Group. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008;15(9):916-921. https://doi.org/10.1111/j.1468-1331.2008.02241.x
  8. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129(3):595-605.
  9. Coles A. Multiple sclerosis. Pract Neurol. 2009;9(2):118-126. https://doi.org/10.1136/jnnp.2008.171132
  10. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg. 2006;108(3):327-332.
  11. O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998;121(3):495-503.
  12. Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci. 2009;282(1-2):106-111. https://doi.org/10.1016/j.jns.2008.11.018
  13. Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. Br J Radiol. 2017;90(1074): 20160721. https://doi.org/10.1259/bjr.20160721
  14. Healy BC, Buckle GJ, Ali EN, Egorova S, Khalid F, Tauhid S, Glanz BI, Chitnis T, Guttmann CRG, Weiner HL, Bakshi R. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017;27(5):481-485. https://doi.org/10.1111/jon.12433
  15. Vågberg M, Axelsson M, Birgander R, Burman J, Cananau C, Forslin Y, Granberg T, Gunnarsson M, von Heijne A, Jönsson L, Karrenbauer VD, Larsson EM, Lindqvist T, Lycke J, Lönn L, Mentesidou E, Müller S, Nilsson P, Piehl F, Svenningsson A, Vrethem M, Wikström J. Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. Acta Neurol Scand. 2017;135(1):17-24. https://doi.org/10.1111/ane.12667
  16. Bergsland N, Horakova D, Dwyer MG, Uher T, Vaneckova M, Tyblova M, Seidl Z, Krasensky J, Havrdova E, Zivadinov R. Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. Neuroimage Clin. 2017;17:444-451. https://doi.org/10.1016/j.nicl.2017.11.002. eCollection 2018
  17. Sbardella E, Petsas N, Tona F, Prosperini L, Raz E, Pace G, Pozzilli C, Pantano P. Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients. PLoS One. 2013;8(5):e63250. https://doi.org/10.1371/journal.pone.0063250
  18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. https://doi.org/10.1212/wnl.33.11.1444
  19. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366
  20. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.
  21. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):662-667.
  22. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M, Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453-1460.
  23. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung H, Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR; Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576-1582.
  24. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-1249. https://doi.org/10.1212/01.wnl.0000237641.33768.8d
  25. Kotov SV, Yakushina TI, Lizhdvoi VYu. Long-term comparative studying efficiency of drugs that change the course of multiple sclerosis. Al’manakh Klinicheskoi Meditsiny. 2011;25:37-40. (In Russ.)

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.